Live Breaking News & Updates on Company Biomodalities

Stay updated with breaking news from Company biomodalities. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Catalent, Inc. Reports Second Quarter Fiscal 2024 Results

Q2 24 net revenue of $1.03 billion decreased 10% as reported, or 11% in constant currency, compared to Q2 23.

Q2 24 net revenue, excluding COVID-related revenue of ~$260 million in Q2’23 and. ....

United States , New Jersey , Alessandro Maselli , Catalent Biomodalities , Novo Holdings , Company Biomodalities , Company Consumer Health , Consumer Health , Consumer Health Segment , Metrics Contract Services , Securities Exchange , Novo Nordisk Foundation , Company Biologics , Catalent Inc , Novo Holding , Chief Executive Officer , Adjusted Net , Net Revenue , Total Net , First Lien Debt , Adjusted Net Income , Net Income , Securities Act , Securities Exchange Act , Annual Report , Quarterly Reports ,

Catalent (CTLT) Reports Prelim Q3 Revenue of $982M, EPS of ($0.10), Reaffirms FY24 Guidance

Catalent (CTLT) Reports Prelim Q3 Revenue of $982M, EPS of ($0.10), Reaffirms FY24 Guidance
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New Jersey , United States , Alessandro Maselli , Paul Surdez , Catalent Biomodalities , Securities Exchange , Consumer Health Segment , Exchange Commission , Company Consumer Health , Consumer Health , Company Biomodalities , Catalent Inc , Metrics Contract Services , Chief Executive Officer , Net Loss , Adjusted Net Income , Net Revenue , Total Net , First Lien Debt , Fiscal Year , Quarterly Report , Late Filing , Securities Exchange Act , Annual Report , Net Income , Adjusted Net ,